

Table of Contents
Week 14 • March 30, 2026
Curated by Manish Goel | multibaggershares.com
⚠️ Anti-F&O Warning: SEBI data shows 90% of F&O traders lose money. F&O is gambling — not investing. Focus on quality businesses for long-term wealth creation. Stay away from tips and intraday trading.
This week’s watchlist features fundamentally strong Indian small & mid-cap businesses selected for their high ROCE, debt-free balance sheets, consistent earnings growth, and strong promoter conviction. Titan Biotech remains our #1 conviction pick — here are other quality names worth watching alongside it.
BSE: 524717 | Biochemicals & Fermentation | Small Cap
Revenue: ₹56.51 Cr | Net Profit: ₹8.53 Cr (↑ 94% YoY) — The business is accelerating. Fermentation-based biochemicals serving pharma, food, and agriculture sectors with dominant niche positioning.
🏆 Why It’s Our #1 Pick: Titan Biotech is the complete package — exceptional long-term compounding track record (49% CAGR over 10 years), accelerating profitability (+94% YoY), almost debt-free, strong promoter conviction, and a tiny market cap of just ₹1,892 Cr. This is precisely the kind of hidden gem that creates generational wealth. Our research on Titan Biotech has been shared with 23 top investors including Mohnish Pabrai.
BSE: 514448 | Adhesives & Sealants | Small Cap (₹887 Cr)
Why Watch: India’s #2 wood adhesive brand (Euro 7000), targeting ₹500 Cr revenue by FY29. Exceptional 50% ROCE + debt-free + 56% profit CAGR. Trading at a 36% discount to peers at just 12.7x P/E. A classic quality compounder in a non-cyclical niche.
BSE: 505355 | Real Estate / Exhibition & Convention Centers | Small-Mid Cap
Why Watch: Owner-operator model with irreplaceable real estate assets (BEC Mumbai — India’s largest exhibition center). Debt-free with 22.4% ROCE. Direct beneficiary of India’s booming MICE (Meetings, Incentives, Conferences, Exhibitions) industry. Consistent cash generation with minimal capex requirements.
BSE: 500265 | Steel Pipes & Tubes | Mid Cap
Why Watch: Zero debt with a blistering 68.9% profit CAGR over 3 years. A key supplier of seamless tubes to oil & gas and power sectors — directly benefiting from India’s infrastructure and energy push. Strong balance sheet gives it pricing power and resilience through commodity cycles.
NSE: GARUDA | Infrastructure & Construction | Small Cap
Why Watch: A newly listed construction gem (Oct 2024) with an exceptional 118% profit CAGR and 30% ROCE, significantly above the industry median of 18%. Negligible debt. Serves government infra and real estate projects. At 21x P/E, still reasonably priced for the quality of growth.
Micro Cap | Infrastructure | Piotroski Score: 7/9
Why Watch: Ultra-micro-cap with explosive metrics — 61.3% ROE, 29.8% ROCE, 42.7% revenue growth, and a Piotroski score of 7/9 indicating strong financial health. At just ₹59 Cr market cap and 15.8x P/E, this is the kind of deeply undervalued name that rewards patient investors. High risk but extraordinary upside potential. Do thorough due diligence.
Watch our complete investing course to master the art of identifying quality compounders — just like Titan Biotech.
▶ Watch Free Investing Course on YouTube
Curated by Manish Goel | multibaggershares.com
Disclaimer: This watchlist is for educational and informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Stock markets involve significant risk. Past performance is not a guarantee of future returns. Please do your own due diligence and consult a SEBI-registered investment advisor before making any investment decisions. The author may or may not hold positions in the stocks mentioned. multibaggershares.com | Manish Goel
Chat with us on WhatsApp